Pfizer (NYSE: PFE), a leading developer of coronavirus vaccines, has made progress in a novel oral antiviral for the disease.
The firm has also announced plans to use its experience developing mRNA-based vaccines to become a major force in the broader vaccines market.
In a statement, the New York-based pharma giant said it was progressing to multiple ascending doses in a Phase I study of its antiviral candidate PF-07321332.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze